Last reviewed · How we verify
Northern Orthopaedic Division, Denmark — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
1 Phase 2
7 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Aethoxysclerol | Aethoxysclerol | marketed | Other | |||
| Pantoprazol | Pantoprazol | marketed | ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1 | Gastroenterology |
Therapeutic area mix
- Other · 4
- Anesthesiology · 1
- Gastroenterology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams Maternity Hospital · 1 shared drug class
- Ain Shams University · 1 shared drug class
- Aligarh Muslim University · 1 shared drug class
- Atlantic Health System · 1 shared drug class
- Aultman Health Foundation · 1 shared drug class
- B.P. Koirala Institute of Health Sciences · 1 shared drug class
- Bagcilar Training and Research Hospital · 1 shared drug class
- Abant Izzet Baysal University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Northern Orthopaedic Division, Denmark:
- Northern Orthopaedic Division, Denmark pipeline updates — RSS
- Northern Orthopaedic Division, Denmark pipeline updates — Atom
- Northern Orthopaedic Division, Denmark pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Northern Orthopaedic Division, Denmark — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/northern-orthopaedic-division-denmark. Accessed 2026-05-16.